Showing results (441-450 of 537) with videos related to

Sort By:
Pageof 54
Annals of the Rheumatic Diseases|August 24, 2006
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyHilary A Capell, Rajan Madhok, Duncan R Porter, et al.
Bone & Joint Research|February 26, 2019
Tranexamic acid toxicity in human periarticular tissuesM McLean, K McCall, I D M Smith, et al.
Annals of the Rheumatic Diseases|March 19, 2024
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritisAndreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, et al.
Arthritis and Rheumatism|March 2, 2012
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trialArthur Kavanaugh, Désirée van der Heijde, Iain B McInnes, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
Scientific Reports|June 7, 2016
IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathyNeal L Millar, Moeed Akbar, Abigail L Campbell, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Annals of the Rheumatic Diseases|December 25, 2015
Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathologyCarmen Huesa, Ana C Ortiz, Lynette Dunning, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Pageof 54